DE102007010252B4 - Kontrollgene zur Normalisierung von Genexpressionsanalysedaten - Google Patents
Kontrollgene zur Normalisierung von Genexpressionsanalysedaten Download PDFInfo
- Publication number
- DE102007010252B4 DE102007010252B4 DE102007010252A DE102007010252A DE102007010252B4 DE 102007010252 B4 DE102007010252 B4 DE 102007010252B4 DE 102007010252 A DE102007010252 A DE 102007010252A DE 102007010252 A DE102007010252 A DE 102007010252A DE 102007010252 B4 DE102007010252 B4 DE 102007010252B4
- Authority
- DE
- Germany
- Prior art keywords
- control
- nucleic acids
- gene
- seq
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 174
- 230000014509 gene expression Effects 0.000 title claims abstract description 83
- 238000010606 normalization Methods 0.000 title claims description 27
- 238000010195 expression analysis Methods 0.000 title claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 60
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 56
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 54
- 239000000523 sample Substances 0.000 claims abstract description 51
- 210000004369 blood Anatomy 0.000 claims abstract description 39
- 239000008280 blood Substances 0.000 claims abstract description 39
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 230000009466 transformation Effects 0.000 claims abstract description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 8
- 238000003633 gene expression assay Methods 0.000 claims abstract description 3
- 206010040047 Sepsis Diseases 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 43
- 238000012360 testing method Methods 0.000 claims description 43
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 36
- 238000002493 microarray Methods 0.000 claims description 35
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 15
- 238000009396 hybridization Methods 0.000 claims description 15
- 208000034486 Multi-organ failure Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 206010040070 Septic Shock Diseases 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- 230000036303 septic shock Effects 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 8
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 8
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 7
- 108700011259 MicroRNAs Proteins 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 239000013610 patient sample Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 238000013459 approach Methods 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 238000013523 data management Methods 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 abstract description 4
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 abstract description 4
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 abstract description 4
- 101000687642 Homo sapiens snRNA-activating protein complex subunit 1 Proteins 0.000 abstract description 4
- 102100022339 Integrin alpha-L Human genes 0.000 abstract description 4
- 102000003810 Interleukin-18 Human genes 0.000 abstract description 4
- 108090000171 Interleukin-18 Proteins 0.000 abstract description 4
- 102100024840 snRNA-activating protein complex subunit 1 Human genes 0.000 abstract description 4
- 108010015181 PPAR delta Proteins 0.000 abstract 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 abstract 2
- 239000013615 primer Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 238000011002 quantification Methods 0.000 description 13
- 210000000601 blood cell Anatomy 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000003491 array Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 3
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 3
- 102100024974 Caspase recruitment domain-containing protein 8 Human genes 0.000 description 3
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 3
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 3
- 101000798902 Homo sapiens Atypical chemokine receptor 4 Proteins 0.000 description 3
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 3
- 101000761247 Homo sapiens Caspase recruitment domain-containing protein 8 Proteins 0.000 description 3
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 3
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 3
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 3
- 101150053046 MYD88 gene Proteins 0.000 description 3
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 3
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 238000013501 data transformation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 206010040560 shock Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 2
- 101710097161 Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 241001077878 Neurolaena lobata Species 0.000 description 1
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- -1 synthetic analogs Proteins 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007010252A DE102007010252B4 (de) | 2007-03-02 | 2007-03-02 | Kontrollgene zur Normalisierung von Genexpressionsanalysedaten |
| ES08716110T ES2358182T3 (es) | 2007-03-02 | 2008-02-28 | Genes de control para la normalización de datos de análisis de la expresión génica. |
| CA002679017A CA2679017A1 (en) | 2007-03-02 | 2008-02-28 | Reference genes for the normalization of gene expression analysis data |
| PCT/EP2008/001582 WO2008107114A2 (de) | 2007-03-02 | 2008-02-28 | Kontrollgene zur normalisierung von genexpressionsanalysedaten |
| JP2009551137A JP5430407B2 (ja) | 2007-03-02 | 2008-02-28 | 遺伝子発現分析データの正規化のための参照遺伝子 |
| US12/529,423 US8338099B2 (en) | 2007-03-02 | 2008-02-28 | Reference genes for the normalization of gene expression analysis data |
| EP08716110A EP2118315B1 (de) | 2007-03-02 | 2008-02-28 | Kontrollgene zur normalisierung von genexpressionsanalysedaten |
| ES10196834.5T ES2524643T3 (es) | 2007-03-02 | 2008-02-28 | Genes control para la normalización de datos de análisis de expresión génica |
| EP10196834.5A EP2392668B1 (de) | 2007-03-02 | 2008-02-28 | Kontrollgene zur Normalisierung von Genexpressionsanalysedaten |
| AT08716110T ATE493517T1 (de) | 2007-03-02 | 2008-02-28 | Kontrollgene zur normalisierung von genexpressionsanalysedaten |
| DE502008002136T DE502008002136D1 (de) | 2007-03-02 | 2008-02-28 | Kontrollgene zur normalisierung von genexpressionsanalysedaten |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007010252A DE102007010252B4 (de) | 2007-03-02 | 2007-03-02 | Kontrollgene zur Normalisierung von Genexpressionsanalysedaten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE102007010252A1 DE102007010252A1 (de) | 2008-09-04 |
| DE102007010252A8 DE102007010252A8 (de) | 2008-12-11 |
| DE102007010252B4 true DE102007010252B4 (de) | 2013-07-04 |
Family
ID=39670079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102007010252A Expired - Fee Related DE102007010252B4 (de) | 2007-03-02 | 2007-03-02 | Kontrollgene zur Normalisierung von Genexpressionsanalysedaten |
| DE502008002136T Active DE502008002136D1 (de) | 2007-03-02 | 2008-02-28 | Kontrollgene zur normalisierung von genexpressionsanalysedaten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE502008002136T Active DE502008002136D1 (de) | 2007-03-02 | 2008-02-28 | Kontrollgene zur normalisierung von genexpressionsanalysedaten |
Country Status (8)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2803339C2 (ru) * | 2017-12-21 | 2023-09-12 | Спидкс Пти Лтд | Определение соотношения нуклеиновых кислот |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060084082A1 (en) | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| DE102007036678B4 (de) | 2007-08-03 | 2015-05-21 | Sirs-Lab Gmbh | Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion |
| DE102008000715B9 (de) * | 2008-03-17 | 2013-01-17 | Sirs-Lab Gmbh | Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen |
| US20110076685A1 (en) * | 2009-09-23 | 2011-03-31 | Sirs-Lab Gmbh | Method for in vitro detection and differentiation of pathophysiological conditions |
| DE102009044085A1 (de) * | 2009-09-23 | 2011-11-17 | Sirs-Lab Gmbh | Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen |
| EP2309001A1 (de) * | 2009-09-23 | 2011-04-13 | SIRS-Lab GmbH | Verfahren zur in vitro Erfassung und Unterscheidung von pathophysiologischen Zuständen |
| PL2639312T3 (pl) * | 2012-03-13 | 2018-01-31 | Siemens Healthcare Gmbh | Oznaczenie immunologiczne do wykrywania miRNA |
| KR102380453B1 (ko) | 2014-11-26 | 2022-03-31 | 도레이 카부시키가이샤 | 소형 rna의 발현량의 보정 방법 및 장치 |
| CA2986787A1 (en) | 2015-05-28 | 2016-12-01 | Immunexpress Pty Ltd | Validating biomarker measurement |
| JP7411979B2 (ja) * | 2019-07-19 | 2024-01-12 | 公立大学法人福島県立医科大学 | 内部標準遺伝子 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005083115A2 (de) * | 2004-03-01 | 2005-09-09 | Sirs-Lab Gmbh | Verfahren zur erkennung von sepsis |
| DE60023496T2 (de) * | 1999-05-25 | 2006-07-27 | Aventis Pharmaceuticals Inc. | Mathematische analyse für die schätzung von veränderungen des niveaus der gen-expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080070235A1 (en) * | 2003-04-02 | 2008-03-20 | Sirs-Lab Gmbh | Method for Recognizing Acute Generalized Inflammatory Conditions (Sirs), Sepsis, Sepsis-Like Conditions and Systemic Infections |
| DE10336511A1 (de) * | 2003-08-08 | 2005-02-24 | Sirs-Lab Gmbh | Verfahren zur Erkennung von schwerer Sepsis |
| US7587279B2 (en) * | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| JP2006170670A (ja) * | 2004-12-13 | 2006-06-29 | Sony Corp | 遺伝子発現量規格化方法、プログラム、並びにシステム |
| US20060136145A1 (en) * | 2004-12-20 | 2006-06-22 | Kuo-Jang Kao | Universal reference standard for normalization of microarray gene expression profiling data |
-
2007
- 2007-03-02 DE DE102007010252A patent/DE102007010252B4/de not_active Expired - Fee Related
-
2008
- 2008-02-28 ES ES10196834.5T patent/ES2524643T3/es active Active
- 2008-02-28 ES ES08716110T patent/ES2358182T3/es active Active
- 2008-02-28 WO PCT/EP2008/001582 patent/WO2008107114A2/de active Application Filing
- 2008-02-28 CA CA002679017A patent/CA2679017A1/en not_active Abandoned
- 2008-02-28 JP JP2009551137A patent/JP5430407B2/ja not_active Expired - Fee Related
- 2008-02-28 EP EP10196834.5A patent/EP2392668B1/de not_active Not-in-force
- 2008-02-28 AT AT08716110T patent/ATE493517T1/de active
- 2008-02-28 DE DE502008002136T patent/DE502008002136D1/de active Active
- 2008-02-28 US US12/529,423 patent/US8338099B2/en not_active Expired - Fee Related
- 2008-02-28 EP EP08716110A patent/EP2118315B1/de not_active Not-in-force
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60023496T2 (de) * | 1999-05-25 | 2006-07-27 | Aventis Pharmaceuticals Inc. | Mathematische analyse für die schätzung von veränderungen des niveaus der gen-expression |
| WO2005083115A2 (de) * | 2004-03-01 | 2005-09-09 | Sirs-Lab Gmbh | Verfahren zur erkennung von sepsis |
Non-Patent Citations (5)
| Title |
|---|
| Chemical Abstract AN 146:435738. In: Acta Medica Nagasakiensia, 51, 2006, 2, 57-63. * |
| Medline Abstract AN 2004 545 916. In: Journal of Biotechnology, 114, 2004, 1-2, 121-124. * |
| Medline Abstract AN 2006 143 439. In: Nutrition (Burbank, Los Angeles, Calif.), 22, 2006, 4, 408-413. * |
| Medline Abstract AN 2006 228 769. In: Journal of Pineal Research, 40, 2006, 4, 305-311. * |
| Thomas D. Schmittgen, Brian A. Zakrajsek: Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. In: J. Biochem. Biophys. Methods, 46, 2000, 69-81. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2803339C2 (ru) * | 2017-12-21 | 2023-09-12 | Спидкс Пти Лтд | Определение соотношения нуклеиновых кислот |
Also Published As
| Publication number | Publication date |
|---|---|
| US8338099B2 (en) | 2012-12-25 |
| ATE493517T1 (de) | 2011-01-15 |
| EP2392668A2 (de) | 2011-12-07 |
| JP5430407B2 (ja) | 2014-02-26 |
| DE102007010252A8 (de) | 2008-12-11 |
| EP2392668A3 (de) | 2012-05-30 |
| EP2118315B1 (de) | 2010-12-29 |
| ES2524643T3 (es) | 2014-12-10 |
| US20100184608A1 (en) | 2010-07-22 |
| DE502008002136D1 (de) | 2011-02-10 |
| EP2118315A2 (de) | 2009-11-18 |
| WO2008107114A3 (de) | 2008-11-20 |
| ES2358182T3 (es) | 2011-05-06 |
| EP2392668B1 (de) | 2014-10-29 |
| CA2679017A1 (en) | 2008-09-12 |
| JP2010519893A (ja) | 2010-06-10 |
| DE102007010252A1 (de) | 2008-09-04 |
| WO2008107114A2 (de) | 2008-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE102007010252B4 (de) | Kontrollgene zur Normalisierung von Genexpressionsanalysedaten | |
| DE102008000715B4 (de) | Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen | |
| EP1863928B1 (de) | Verwendung von genaktivitäts-klassifikatoren für die in vitro klassifizierung von genexpressionsprofilen von patienten mit infektiösem/nichtinfektiösem multiorganversagen | |
| KR20140044375A (ko) | 알츠하이머병을 나타내는 마이크로rna 바이오마커들 | |
| DE102007036678B4 (de) | Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion | |
| EP1721002A2 (de) | Verfahren zur erkennung von sepsis | |
| WO2007042165A1 (de) | Verfahren zur diagnose thromboembolischer erkrankungen und koronarer herzerkrankungen | |
| WO2007124820A2 (de) | Verfahren zur in-vitro überwachung postoperativer veränderungen nach lebertransplantation | |
| DE102004049897B4 (de) | Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens | |
| WO2011036091A1 (de) | Verfahren zur in vitro erfassung und unterscheidung von pathophysiologischen zuständen | |
| WO2005106020A1 (de) | Verfahren zur vorhersage des individuellen krankheitsverlaufs bei sepsis | |
| Nishigaki et al. | Extensive screening system using suspension array technology to detect mitochondrial DNA point mutations | |
| EP3599288B1 (en) | Diagnosis and treatment of psoriatic arthritis | |
| EP4008794A1 (en) | Analysis method and kit | |
| KR102720023B1 (ko) | 바이설파이트 변환 평가용 키트 및 이를 이용한 평가 방법 | |
| EP2985352A1 (de) | Verfahren zur in vitro erfassung und unterscheidung von pathophysiologischen zuständen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8196 | Reprint of faulty title page (publication) german patentblatt: part 1a6 | ||
| OP8 | Request for examination as to paragraph 44 patent law | ||
| R016 | Response to examination communication | ||
| R018 | Grant decision by examination section/examining division | ||
| R020 | Patent grant now final |
Effective date: 20131005 |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |